J. Plumb

发表

Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.

D. Singer, S. Goldhaber, S. Sorensen, 2009, American heart journal.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

Paul Robinson, R. Gani, M. Cowie, 2012, Heart.

Annual Cost of Erectile Dysfunction to UK Society

J. Plumb, J. Guest, 1999, PharmacoEconomics.

Economic Impact of Tibolone Compared with Continuous-Combined Hormone Replacement Therapy

J. Plumb, J. Guest, 2000, PharmacoEconomics.

Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty

B. Eriksson, J. Plumb, J. Caprini, 2008, Thrombosis and Haemostasis.

How guidance on the use of interventional procedures is produced in different countries: An international survey

Bruce Campbell, Georgios Lyratzopoulos, J. Plumb, 2009, International Journal of Technology Assessment in Health Care.

Comparison of the assessment of five new interventional procedures in different countries

J. Plumb, G. Lyratzopoulos, B. Campbell, 2010, International Journal of Technology Assessment in Health Care.

Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients

J. Plumb, A. Clemens, T. V. van Staa, 2011, Thrombosis and Haemostasis.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.

J. Plumb, G. Dolan, I. Brenkel, 2009, Clinical therapeutics.

Strengthening pharma's contract with society: the value of trusted partnerships between pharma and healthcare facilitated by real-world data.

C. Pashos, J. Plumb, R. LoCasale, 2020, Journal of comparative effectiveness research.

How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation?

J. Plumb, S. Rietbrock, T. V. van Staa, 2009, Thrombosis and Haemostasis.

Cost-effectiveness of Viridal Duo compared to MUSE and Viagra in the treatment of erectile dysfunction in the UK - a preliminary model

J. Plumb, J. Guest, 1999 .

Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care

J. Plumb, H. Campbell, S. Edwards, 2006, The European Journal of Health Economics.

Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma.

J. Plumb, A. Lloyd, J. Hutchinson, 2002, Respiratory medicine.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement

J. Plumb, G. Dolan, I. Brenkel, 2009, Thrombosis and Haemostasis.

Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis

J. Plumb, S. Edwards, 2002 .

Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement: A Systematic Review

B. Monz, J. Plumb, A. Clemens, 2012, PharmacoEconomics.

Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?

J. Plumb, S. Rietbrock, A. Gallagher, 2008, Journal of thrombosis and haemostasis : JTH.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective

S. Connolly, S. Sorensen, J. Plumb, 2011, Thrombosis and Haemostasis.

Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control.

J. Plumb, A. Tukiendorf, P. McEwan, 2009, Thrombosis research.

Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate

G. Lip, J. Plumb, A. Clemens, 2010, Thrombosis and Haemostasis.

Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme.

Emma Heeley, Tjeerd van Staa, J. Plumb, 2008, American heart journal.

Quality of INR Control and Outcomes Following Venous Thromboembolism

J. Plumb, F. de Vries, A. Clemens, 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years

B. Monz, J. Plumb, S. Wolowacz, 2008, Current medical research and opinion.

How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review

J. Plumb, S. Chambers, S. Chadda, 2009, International journal of laboratory hematology.

Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta‐analyses and real‐world evidence on antiepileptic drugs

M. Baulac, J. Plumb, S. Borghs, 2020, Epilepsia.

Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?

J. Plumb, S. Borghs, J. Signorovitch, 2017, CNS Drugs.

Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature

J. Plumb, G. Dolan, S. Collins, 2008 .

Bridging the Gap Between RCTs and RWE Through Endpoint Selection

N. Dreyer, C. Pashos, J. Plumb, 2020, Therapeutic Innovation & Regulatory Science.

How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review

J. Plumb, S. Chambers, S. Chadda, 2009, International journal of laboratory hematology.

Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.

D. Singer, S. Goldhaber, S. Sorensen, 2009, American heart journal.

Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate

G. Lip, J. Plumb, A. Clemens, 2010, Thrombosis and Haemostasis.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.

J. Plumb, G. Dolan, I. Brenkel, 2009, Clinical therapeutics.